194 related articles for article (PubMed ID: 12939188)
1. [Lamivudine treatment consensus from relative experts in 2003].
Lamivudine Clinical Practice Group
Zhonghua Gan Zang Bing Za Zhi; 2003 Aug; 11(8):497-9. PubMed ID: 12939188
[No Abstract] [Full Text] [Related]
2. [Lamivudine treatment consensus from relative experts].
Lamivudine Clinical Practice Group
Zhonghua Gan Zang Bing Za Zhi; 2002 Apr; 10(2):157-8. PubMed ID: 12108391
[No Abstract] [Full Text] [Related]
3. [Effects of lamivudine and interferon-alpha combination therapy on chronic hepatitis B].
Tang Y; Chen G; Zheng R
Zhonghua Gan Zang Bing Za Zhi; 2002 Apr; 10(2):89. PubMed ID: 11983118
[No Abstract] [Full Text] [Related]
4. Changing landscape of antiviral resistance management in chronic hepatitis B.
Nguyen T; Locarnini S; Desmond P
J Gastroenterol Hepatol; 2008 Sep; 23(9):1314-7. PubMed ID: 18853991
[No Abstract] [Full Text] [Related]
5. [Lamivudine treatment for hepatitis B].
Lamivudine Clincal Practice Group
Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):425-8. PubMed ID: 15487066
[No Abstract] [Full Text] [Related]
6. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
7. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
8. [Combination therapy of lamivudine and HB vaccine for the treatment of chronic hepatitis B].
Ishikawa T; Kakumu S
Nihon Rinsho; 2004 Aug; 62 Suppl 8():331-5. PubMed ID: 15453340
[No Abstract] [Full Text] [Related]
9. [Interferon therapy for chronic hepatitis B].
Tang WL; Xie Q
Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):726-9. PubMed ID: 19874685
[No Abstract] [Full Text] [Related]
10. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
[TBL] [Abstract][Full Text] [Related]
11. Chronic hepatitis B: back to the future with HBsAg.
Moucari R; Lada O; Marcellin P
Expert Rev Anti Infect Ther; 2009 Aug; 7(6):633-6. PubMed ID: 19681689
[No Abstract] [Full Text] [Related]
12. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy.
Bourne EJ; Dienstag JL; Lopez VA; Sander TJ; Longlet JM; Hall JG; Kwiatkowski RW; Wright T; Lai CL; Condreay LD
J Viral Hepat; 2007 Jan; 14(1):55-63. PubMed ID: 17212645
[TBL] [Abstract][Full Text] [Related]
13. The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B.
Shindo M; Hamada K; Nishioji K; Muramatsu A; Oda Y; Okuno T
J Gastroenterol; 2004; 39(3):260-7. PubMed ID: 15065004
[TBL] [Abstract][Full Text] [Related]
14. [Bringing the antiviral therapy home for chronic hepatitis B patients: host immunity influences the efficacy and disease prognosis].
Wang FS; Zhang JY
Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):164-6. PubMed ID: 19554778
[No Abstract] [Full Text] [Related]
15. [Treatment and selection criteria for chronic hepatitis B].
Gunji T; Omata M
Nihon Rinsho; 2004 Aug; 62 Suppl 8():309-12. PubMed ID: 15453336
[No Abstract] [Full Text] [Related]
16. Hepatitis B virus infection--natural history and clinical consequences.
Ganem D; Prince AM
N Engl J Med; 2004 Mar; 350(11):1118-29. PubMed ID: 15014185
[No Abstract] [Full Text] [Related]
17. Antiviral therapy for chronic hepatitis B.
Jafri SM; Lok AS
Clin Liver Dis; 2010 Aug; 14(3):425-38. PubMed ID: 20638023
[TBL] [Abstract][Full Text] [Related]
18. Events occurring at the time of breakthrough hepatitis during lamivudine treatment for chronic hepatitis B.
Yokosuka O
J Gastroenterol; 2004 Aug; 39(8):813-4. PubMed ID: 15338383
[No Abstract] [Full Text] [Related]
19. Therapy of chronic hepatitis B: new goals and new treatments.
Mauss S
Minerva Med; 2009 Dec; 100(6):447-58. PubMed ID: 20010480
[TBL] [Abstract][Full Text] [Related]
20. Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B.
Cheong JY; Cho SW; Yoo JH; Hong SP; Kim SO; Yoo WD; Kim JH
Hepatogastroenterology; 2008; 55(84):1029-33. PubMed ID: 18705323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
